The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 270 members and is the leading global advocacy organization in this field. www.alliancerm.org
Chardan is a global boutique investment bank focused on companies that offer superior investment return prospects, based on the potential to create real value for society. In following vector gene therapy, small RNA therapy, and gene editing companies, Chardan covers more genetic medicines names than any other bank globally. Chardan is known for its market impact, communicating on fundamental sector value drivers (e.g. via the predictive Chardan Gene Therapy Framework), and has successfully raised more than $1.4 billion for genetic medicines companies since 2015. www.chardan.com | email@example.com | 646-465-9018
PNC Healthcare offers a fully integrated suite of tools, solutions and advisory services to help providers and payers maximize working capital, streamline administrative processes, mitigate financial risk and access capital for investment and growth. With more than 25 years of experience developing solutions for the healthcare sector, our clients include acute-care hospitals and systems, physician practice groups, billing companies, labs, ambulatory care companies, home healthcare, extended care, healthcare payers and group purchasing organizations. Clients are both for profit as well as not-for profit organizations. www.pnc.com/healthcare
As one of North America’s leading full-service investment firms, Raymond James offers a full array of capital markets services, strategic advice and planning for every stage of the business life cycle. Our focus is on remaining agile and taking a personal approach to serving the needs of growth companies and the institutional and retail communities that invest in them. Raymond James Equity Research is a cornerstone of the organization. Raymond James and its affiliates in Canada and Europe employ more than 70 research analysts who cover nearly 1,300 companies in nine highly focused industries: Consumer, Energy, Financial Services, Healthcare, Industrial, Mining and Natural Resources, Real Estate, Technology and Communications, and Transportation. We are a top provider of equity research in both North America and globally in terms of companies covered. www.raymondjames.com
Solebury Trout partners with private and public companies across all industries, helping management teams prepare for capital raising, access investors and tackle complex investor relations and corporate communications issues. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country. www.soleburytrout.com
Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, cGMP facilities and an international track record makes Cognate one of the most experienced contract manufacturers of cell-based products in the world today. www.cognatebioservices.com
Crossover Search is a boutique search firm dedicated to the life sciences industry. Since 2008, we have partnered with a broad range of innovative pharmaceutical, biotechnology, medical device and diagnostics companies, primarily in the US and Europe. Our expertise spans the entire industry, and our track record includes successful placements in various business units, functions and therapeutic areas. We provide professional search and recruiting services aimed at ensuring that you have the talent you need, from the lab to the boardroom, to achieve your scientific and business goals. At our core, we are a firm built on the belief that relationships are the lifeblood of our business. This goes for clients, candidates and our team. www.crossoversearch.com
Cryoport is the premier provider of cold chain logistics solutions to the life sciences industry through our purpose-built proprietary packaging, information technology and specialized logistics expertise. We provide leading-edge cold chain logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide including points-of-care, CROs, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. Cryoport’s unparalleled information technology centers around our proprietary Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Our state-of-the-art technology also includes our innovative SmartpakII™ Condition Monitoring System, which provides visibility of the location and the key aspects of critical shipments. The SmartpakII™ works in conjunction with our Cryoportal™ to provide real-time information reporting about shipments, integrated condition monitoring, logistics and shipper qualification performance in a single data steam. Cryoport also has a dedicated 24/7/365 customer service team to proactively monitor each shipment, allowing for invention when necessary. www.cryoport.com
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts Phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America and Asia-Pacific. www.ctifacts.com
Defined Health advises senior management at life sciences clients on the value of compounds and technology platforms in development, from pre-IND to indication prioritization and sequencing, repurposing, reformulation and life cycle management. Our scientifically trained consultants leverage the firm’s 30 years of experience with evaluations that are grounded in the science, and informed by an unparalleled understanding of current and evolving clinical practices, development and regulatory issues, competitive commercial dynamics and pricing, reimbursement and market access practices. In addition to our core Opportunity Assessment business, we have a large Search and Evaluation practice, wherein we identify and assess relevant opportunities for therapeutic area expansion, as well as a Strategy practice that addresses broader corporate development initiatives — therapeutic and disease area and market entry strategies. Our clients include 10 of the top 20 pharmacos, five of the top 10 large cap biotechs, and scores of specialty pharma and pre-commercial biotech companies, as well as several royalty investors and two of the top private equity firms. We are proud to have an 80% repeat and referral client base. Find out more about Defined Health and view our recent presentations on topical and therapeutic area specific subjects at www.definedhealth.com.
Kawasaki is committed to providing customers unique business solutions with our innovative technologies to meet diverse societal needs worldwide. Our newly developed Automated Cell Processing System: AUTO CULTURE® is intended for use in clinical research, practice and commercialization to support advances in regenerative medicine and cell therapy featuring the following capabilities: Safe, stable and scalable automated production of cells; Contamination control; High versatility and expandability; Reliable traceability. With our system you can reduce the initial investment in your cell processing facility (CPF) as well as the running cost. Search “Kawasaki AUTO CULTURE®” for more information.
KBI Biopharma is a biopharmaceutical contract development and manufacturing organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs. KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates four facilities: Durham and Research Triangle Park, NC; Boulder, CO; and The Woodlands, TX. www.kbibiopharma.com
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell and viral therapeutic manufacturing. www.lonza.com
Medpace is a global full-service Clinical Research Organization (CRO) providing comprehensive development services for drug, biologic and device programs with a specialized focus on advanced therapies including cell and gene therapies. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department, across six continents, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. Learn more about Medpace’s focus on cellular, tissue and gene therapy medicines at www.medpace.com.
PCT is the global cell therapy manufacturing and development service platform of the Hitachi Chemical Regenerative Medicine Business Sector, leveraging nearly two decades of PCT platform experience exclusively focused on the cell therapy industry. The PCT service platform includes contract development and manufacturing organization (CDMO) services, at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing and manufacturing development.
Hitachi Chemical Advanced Therapeutics Solutions (HCATS), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. (Hitachi Chemical) representing Hitachi Chemical’s Regenerative Medicine Business Sector in the U.S. HCATS’ vision is a world in which transformative cell-based therapeutics are accessible to all, and its mission is to provide its clients with high-quality, scalable, innovative, reliable and cost-efficient manufacturing platforms and services, such as the PCT platform, to advance commercialization of cellular therapies. Robert Preti, Ph.D., the CEO and President of HCATS is the General Manager of the Hitachi Chemical Regenerative Medicine Business Sector. www.pctcelltherapy.com
Antenna is a leading communications agency working in life sciences, helping entrepreneurial companies achieve breakthrough velocity. Our unrivaled domain expertise means we hit the ground running on day one, and our genuine passion for the industry yields better results across the board. From landing on the front page of The Wall Street Journal to strategically targeting the medical or investor communities, Antenna’s clients earn unparalleled opportunities to tell their stories to global audiences. www.antennagroup.com
Edison is one of the largest investment intelligence and access firms globally, staffed by over 120 professionals. Equity research is a key area of expertise, and our team of 80+ analysts produce research on over 700 companies. We also specialise in running non-deal roadshows throughout Europe and North America, arranging over 2,000 investor meetings last year, as well as a range of other services including perception surveys, EdisonTV and Commercial Due Diligence. Our client base consists of approximately 100 leading institutional investors and 500 corporate clients. We have a globally recognised research brand supported by offices in North America, Continental Europe and Asia Pacific, and a particular strength in healthcare with one of the largest and most respected team of healthcare analysts worldwide. www.edisongroup.com
Informa Pharma Intelligence delivers the data and insights needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. Its market leading products cover every perspective of key diseases, clinical trials, drug approvals or R&D projects and are supported by the breadth and depth its data and insights. www.pharmaintelligence.informa.com